SCHEMBL29506445

SCHEMBL29506445

Cc1cc(Nc2ncc3c(n2)N2CCN=C2N(c2c(F)cccc2F)C3=O)ccc1N1CCN(C)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 6/20 0.59
▸ TNK2 Q07912 3/20 0.51
▸ JAK2 O60674 4/20 0.48
▸ SRC P12931 2/20 0.48
▸ FLT3 P36888 3/20 0.48
▸ EGFR P00533 4/20 0.47
▸ CSF1R P07333 3/20 0.47
▸ JAK3 P52333 4/20 0.46
▸ KDR P35968 2/20 0.46
▸ AXL P30530 2/20 0.46
▸ CDC7 O00311 1/20 0.46
▸ PLK4 O00444 1/20 0.46
▸ CHEK1 O14757 1/20 0.46
▸ AURKA O14965 1/20 0.46
▸ DCLK1 O15075 1/20 0.46
▸ PDPK1 O15530 1/20 0.46
▸ DAPK3 O43293 1/20 0.46
▸ ROCK2 O75116 1/20 0.46
▸ PRKD3 O94806 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373336 1.00 WEE1 (0.59) WEE1TNK2JAK2SRCFLT3
SCHEMBL29506475 0.97 WEE1 (0.57) WEE1TNK2JAK2SRCFLT3
SCHEMBL21373275 0.97 WEE1 (0.57) WEE1TNK2JAK2SRCFLT3
SCHEMBL21373447 0.95 WEE1 (0.65) WEE1TNK2JAK2SRCEGFR
SCHEMBL29506571 0.95 WEE1 (0.65) WEE1TNK2JAK2SRCEGFR
SCHEMBL21373360 0.94 WEE1 (0.56) WEE1TNK2JAK2SRCFLT3
SCHEMBL29506542 0.94 WEE1 (0.56) WEE1TNK2JAK2SRCFLT3
SCHEMBL21373292 0.92 WEE1 (0.59) WEE1TNK2JAK2SRCFLT3
SCHEMBL29506488 0.92 WEE1 (0.59) WEE1TNK2JAK2SRCFLT3
SCHEMBL21373323 0.91 WEE1 (0.67) WEE1TNK2JAK2SRCEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback